Chester County News and Community Website
WASHINGTON, D.C. — This week, in a significant step for the medical world and hope for patients, the U.S. Food and Drug Administration expanded the approval of Elevidys, a gene …
FDA Broadens Approval of Elevidys Gene Therapy for Duchenne Muscular Dystrophy Patients Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced the first patient has been dosed in its Phase 3 liMeliGhT clinical trial for OCU400, a gene therapy candidate for retinitis pigmentosa …
Ocugen Doses First Patient in Phase 3 Trial for Retinitis Pigmentosa Therapy Read More
GLENOLDEN, PA — The Charcot-Marie-Tooth Association (CMTA) has announced a $240,000 investment in gene replacement therapy targeting CMT4A, a severe form of the disease. This initiative, led by Dr. Xin …
CMTA Invests $240K in Gene Therapy for Rare Nerve Disorder Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced a positive outcome from the Data and Safety Monitoring Board (DSMB) review of its Phase 1/2 ArMaDa clinical trial for OCU410, a …
Ocugen’s Gene Therapy Shows Promise in Early Trial for Age-Related Macular Degeneration Read More
PHILADELPHIA PA — Greater Philadelphia has emerged as a powerhouse in the cell and gene therapy industry, housing almost 10 percent of the world’s companies in this rapidly expanding sector. …
Greater Philadelphia Dominates Cell and Gene Therapy Landscape – A Beacon of Innovation and Employment Read More
PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) has announced a significant milestone in cancer treatment. The company recently dosed the first patient in its Phase 1 clinical trial of …
Carisma Therapeutics Launches First Human Trial for CAR-Monocyte Therapy Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focusing on innovative therapies, announced the completion of dosing in the second cohort of its groundbreaking GARDian clinical trial for …
Ocugen Advances with Phase 1/2 Trial for Stargardt Disease Treatment Read More
WAYNE, PA — XyloCor Therapeutics, Inc. recently revealed the final results from the Phase 2 segment of its EXACT clinical trial at the Society for Cardiovascular Angiography & Interventions (SCAI) …
XyloCor Therapeutics Announces Promising Results for Gene Therapy in Treating Refractory Angina Read More
PARSIPPANY, NJ & KING OF PRUSSIA, PA — Ferring Pharmaceuticals has teamed up with SK pharmteco to scale up the commercial manufacturing capacity of ADSTILADRIN (nadofaragene firadenovec-vncg), a gene therapy …
Ferring Pharmaceuticals Partners with SK pharmteco to Boost Gene Therapy Supply Read More MALVERN, PA — In a significant advancement for retinitis pigmentosa (RP) treatment, Ocugen, Inc. (NASDAQ: OCGN) has received favorable scientific advice from the European Medicines Agency (EMA) regarding its pivotal …
Ocugen’s Gene Therapy OCU400 Moves Closer to European Market with EMA’s Positive Opinion Read More